Clinical trial
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter Study of Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype (SWIFT 02)
NCT06947967 is registered in ClinicalTrials.gov with Chipscreen Biosciences, Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter Study of Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype (SWIFT 02)
- Lead sponsor
- Chipscreen Biosciences, Ltd.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- August 12, 2025
- Completion date
- December 31, 2032
- Enrollment
- 224 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.